These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 9124752)

  • 1. Biologic tumor markers, lymph node status, and decision about adjuvant chemotherapy for breast cancer.
    Velanovich V
    Am Surg; 1997 Apr; 63(4):330-3. PubMed ID: 9124752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma.
    Barth A; Craig PH; Silverstein MJ
    Cancer; 1997 May; 79(10):1918-22. PubMed ID: 9149018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor.
    Fehm T; Maul H; Gebauer S; Scharf A; Baier P; Sohn C; Jäger W; Gebauer G
    Strahlenther Onkol; 2005 Sep; 181(9):580-6. PubMed ID: 16170485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reasoning with uncertainty in pathology: artificial neural networks and logistic regression as tools for prediction of lymph node status in breast cancer patients.
    Marchevsky AM; Shah S; Patel S
    Mod Pathol; 1999 May; 12(5):505-13. PubMed ID: 10349989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
    Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
    Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
    J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer.
    Katz A; Smith BL; Golshan M; Niemierko A; Kobayashi W; Raad RA; Kelada A; Rizk L; Wong JS; Bellon JR; Gadd M; Specht M; Taghian AG
    J Clin Oncol; 2008 May; 26(13):2093-8. PubMed ID: 18445838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Flow cytophotometry parameters, hormone receptors and axillary lymph node status as prognostic factors in primary breast cancer].
    Kaufmann M; Feichter GE; Nhila A; Klinga K; Abel U
    Geburtshilfe Frauenheilkd; 1988 Oct; 48(10):705-9. PubMed ID: 3234702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical features and prognostic factors of small breast cancer with multiple axillary lymph node metastasis].
    Liao YQ; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):615-8. PubMed ID: 18210884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
    Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
    Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How important is the axillary nodal status for adjuvant treatment decisions at a breast cancer multidisciplinary tumor board? A survival analysis.
    Reimer T; Fietkau R; Markmann S; Stachs A; Gerber B
    Ann Surg Oncol; 2008 Feb; 15(2):472-7. PubMed ID: 17987339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy.
    Reitsamer R; Peintinger F; Rettenbacher L; Prokop E
    J Surg Oncol; 2003 Oct; 84(2):63-7. PubMed ID: 14502778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
    Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
    Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of nonsentinel node metastasis in patients with breast cancer after sentinel node metastasis.
    Joseph KA; El-Tamer M; Komenaka I; Troxel A; Ditkoff BA; Schnabel F
    Arch Surg; 2004 Jun; 139(6):648-51. PubMed ID: 15197092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of DNA flow cytometry and hormone receptors with axillary lymph node status in patients with carcinoma of the breast.
    Friedman NS; Freedman MD
    Md Med J; 1994 Nov; 43(11):963-5. PubMed ID: 7808198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.